Inactive Instrument

Press Releases LA JOLL Nasdaq

Equities

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

La Jolla : Pharmaceutical Company : Receives Positive Opinion from European Orphan Committee for LJPC-401	15-09-11	BU
La Jolla : Pharmaceutical Company : Announces Pricing of Underwritten Offering of Common Stock	15-09-10	BU
La Jolla : Pharmaceutical Company : Announces Proposed Underwritten Offering of Common Stock	15-09-09	BU
La Jolla : Pharmaceutical Company : Receives Orphan Drug Designation for Two Novel Compounds for Fibrodysplasia Ossificans Progressiva	15-08-18	BU
La Jolla : Pharmaceutical Company : and Vanderbilt University Enter Exclusive Research and License Agreement Covering Novel BMP Type-I Receptor Inhibitors	15-08-18	BU
La Jolla : Pharmaceutical Company : Announces FDA Acceptance of IND for LJPC-401	15-08-11	BU
La Jolla : Pharmaceutical Company : Announces Second Quarter 2015 Financial Results and Recent Corporate Progress	15-08-07	BU
La Jolla : Pharmaceutical Company : Announces Exclusive Worldwide License Agreements Covering LJPC-30Sa and LJPC-30Sb	15-08-05	BU
LA JOLL : Lakhmir S. Chawla, M.D. Receives the International Vicenza Award	15-07-01	BU
La Jolla : Pharmaceutical Company : to Provide Corporate Overview at the JMP Securities Life Science Conference 2015	15-06-17	BU
La Jolla : Pharmaceutical Company : to Provide Corporate Overview at the Jefferies 2015 Global Healthcare Conference	15-05-27	BU
La Jolla : Pharmaceutical Company : Acquires Rights to Next-Generation Gentamicin Derivatives	15-05-07	BU
La Jolla : Pharmaceutical Company : Announces Portfolio Reprioritization	15-05-07	BU
La Jolla : Pharmaceutical Company : Announces First Quarter 2015 Financial Results and Corporate Highlights	15-04-29	BU
La Jolla : Pharmaceutical Company : Appoints Lakhmir S. Chawla, M.D., as Chief Medical Officer	15-04-27	BU
La Jolla : Pharmaceutical Company : Announces Additions to LJPC-401 Advisory Board	15-04-22	BU
La Jolla : Pharmaceutical Company : Appoints Dennis Mulroy as Chief Financial Officer	15-04-06	BU
La Jolla : Pharmaceutical Company : Announces Initiation of Phase 3 Clinical Trial of LJPC-501 in Catecholamine-Resistant Hypotension	15-03-24	BU
La Jolla : Pharmaceutical Company : Announces Initiation of Phase 2b Clinical Trial of GCS-100 in Advanced Chronic Kidney Disease	15-03-18	BU
La Jolla : Pharmaceutical Company : Announces Fourth Quarter and Full Year 2014 Financial Results and Corporate Highlights	15-03-16	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases LA JOLL Nasdaq

Equities

Press Releases

Filters